We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
American Renal Associates Holdings Inc | NYSE:ARA | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 11.52 | 0 | 01:00:00 |
American Renal Associates Holdings, Inc. (NYSE: ARA) (“ARA” or the “Company”), a leading provider of outpatient dialysis services, today announced that it has named Don E. Williamson, M.D. as Executive Vice President and Chief Operating Officer (COO) effective today. Williamson has served as one of ARA’s National Chief Medical Officers since 2011, and has been an ARA physician partner since 2002. Williamson has more than 26 years of experience as a nephrologist, and he most recently served as President, CEO and Managing Partner of Nephrology Associates, P.C., a leading nephrology practice group based in Georgia that employs 13 providers and more than 35 staff. Williamson is a graduate of Mercer University and the Medical College of Georgia.
Joseph (Joe) Carlucci, Chairman and Chief Executive Officer, said, “Don is a proven clinical leader with outstanding operational skills, and he is passionate about our Core Values. Don brings to the COO role a deep understanding of the dialysis industry and the practice of nephrology, and he possesses a clear vision for how ARA’s physician-driven partnership model can drive quality results for patients and key stakeholders. Don’s professional accomplishments are impressive, and he is respected inside and outside of ARA as a thoughtful and results-oriented leader who has dedicated his career to improving the lives of patients with kidney disease. We are fortunate to have Don join our leadership team, and, on behalf of the entire ARA family, I am very pleased to welcome Don on board as COO.”
“I am honored to have the opportunity to join ARA’s leadership team. I am committed to helping ARA deliver the best clinical performance in the dialysis industry, while also helping ARA drive growth and innovation. I look forward to working with ARA’s staff and physician partners nationwide so we can continue to build on the success of the Company’s clinically-integrated operating model together,” said Williamson.
About American Renal Associates
American Renal Associates Holdings, Inc. (NYSE: ARA) is a leading provider of outpatient dialysis services in the United States. As of June 30, 2017, ARA operated 217 dialysis clinic locations in 25 states and the District of Columbia serving approximately 15,000 patients with end stage renal disease. ARA operates exclusively through a physician partnership model, in which it partners with more than 385 local nephrologists to develop, own and operate dialysis clinics. ARA’s Core Values emphasize taking good care of patients, providing physicians with clinical autonomy and operational support, hiring and retaining the best possible staff and providing best practices management services. For more information about American Renal Associates, visit www.americanrenal.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, which have been included in reliance of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, involve risks and uncertainties and assumptions relating to our operations, financial condition, business, prospects, growth strategy and liquidity, which may cause our actual results to differ materially from those projected by such forward-looking statements, and the Company cannot give assurances that such statements will prove to be correct. You can identify forward-looking statements because they do not relate strictly to historical or current facts. These statements may include words such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “outlook,” “potential,” “project,” “projection,” “plan,” “intend,” “seek,” “may,” “could,” “would,” “will,” “should,” “can,” “can have,” “likely,” the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events.
The forward-looking statements appear in the third paragraph of this press release and include statements regarding our future performance, growth and strategy. All forward-looking statements are subject to risks and uncertainties, including but not limited to those risks and uncertainties described in “Risk Factors” and “Special Note Regarding Forward-Looking Statements” in our Annual Report on Form 10-K for the year ended December 31, 2016, our 10-Q for the quarter ended March 31, 2017 and our 10-Q for the quarter ended June 30, 2017 filed with the Securities and Exchange Commission, that may cause actual results to differ materially from those that we expected.
Some of the factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements include, among others, the following:
The forward-looking statements made in this press release are made only as of the date of the hereof. Except as required by law, we undertake no obligation to update any forward-looking statement, whether as a result of new information or otherwise. More information about potential factors that could affect our business and financial results is included in our filings with the Securities and Exchange Commission.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170919006490/en/
American Renal Associates Holdings, Inc.Darren Lehrich, 978-522-6063SVP Strategy & Investor Relationsdlehrich@americanrenal.com
1 Year American Renal Associates Chart |
1 Month American Renal Associates Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions